title: Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus.
abstract: This was an exploratory analysis comparing the safety and efficacy of immunoadsorption (IAS) combination therapy in severe systemic lupus erythematosus (SLE) receiving corticosteroid pulse and immunosuppressant treatment. Patients enrolled all had predominant organ involvement including proteinuria, thrombocytopenia, pericardial effusion, and cerebral involvement requiring corticosteroid pulse treatment. Fifty-two patients in study group received IAS plus corticosteroid and cyclophosphamide treatment. Fifty-two patients in non-IAS group received corticosteroid and cyclophosphamide treatment. Outcome measurement included C3, dsDNA, AnuA, and SLE disease activity index (SLEDAI) 2k score and in particular cases, proteinuria quantification and platelet count. Disease activity dropped significantly in both groups. Improvement of disease activity markers was more significant in study group than that in non-IAS group. The lower dosage of steroid in study group suggested the steroid-sparing effect of IAS. No severe adverse effect occurred during IAS. Our study suggested IAS as an additional therapy to steroid pulse and immunosuppressant in treating severe SLE.
authors.affiliation: Rheumatology Department, The Fourth People's Hospital of Shenzhen, Shenzhen, China. huangjx@hku-szh.org.|Rheumatology Department, The University of Hong Kong-Shenzhen Hospital, Haiyuan Road, Shenzhen, 518000, China. huangjx@hku-szh.org.
authors.forename: Jinxian
authors.initials: J
authors.lastname: Huang
authors.affiliation: The Third People's Hospital of Shenzhen, Shenzhen, China.
authors.forename: Guoxiang
authors.initials: G
authors.lastname: Song
authors.affiliation: Rheumatology Department, The Fourth People's Hospital of Shenzhen, Shenzhen, China.
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Yin
authors.affiliation: Rheumatology Department, The Fourth People's Hospital of Shenzhen, Shenzhen, China.
authors.forename: Weizhen
authors.initials: W
authors.lastname: He
authors.affiliation: Rheumatology Department, The University of Hong Kong-Shenzhen Hospital, Haiyuan Road, Shenzhen, 518000, China.
authors.forename: Lijun
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Rheumatology Department, The Fourth People's Hospital of Shenzhen, Shenzhen, China.
authors.forename: Weihong
authors.initials: W
authors.lastname: Kong
authors.affiliation: Rheumatology Department, The Fourth People's Hospital of Shenzhen, Shenzhen, China.
authors.forename: Zhizhong
authors.initials: Z
authors.lastname: Ye
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D010956:Plasmapheresis / Q000379:methods*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide
keywords: Chinese; Immunoadsorption; Systemic lupus erythematosus